Search - tctmd.com

Displaying 361 - 374 of 374

Sort: Relevancy | Date

News Industry News

Hansen Medical® Announces Successful Enrollment of Initial Cohort in Artisan® U.S. Clinical Trial

July 06, 2015

News Industry News

SentreHEART Receives FDA Approval for the AMAZE Trial to Evaluate LARIAT Ligation of the Left Atrial

June 29, 2015

News Industry News

Medtronic Announces Acquisition of CardioInsight Technologies, Developer of Non-Invasive Cardiac Mapping System

June 19, 2015

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Conference News ESC 2012

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Yael L. Maxwell

August 29, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

News Daily News

Procedural Complications Not to Blame for Death After PCI

March 06, 2012

News Daily News

Live Case Procedures Just as Safe as in Daily Practice

Caitlin E. Cox

February 21, 2012

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Conference News

PARTNER: TAVI Cost Effective Compared With Standard Care

Jason Kahn

April 03, 2011

Advertisement

Hansen Medical® Announces Successful Enrollment of Initial Cohort in Artisan® U.S. Clinical Trial

SentreHEART Receives FDA Approval for the AMAZE Trial to Evaluate LARIAT Ligation of the Left Atrial

Medtronic Announces Acquisition of CardioInsight Technologies, Developer of Non-Invasive Cardiac Mapping System

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Innovation in Intervention: Perspectives from Industry

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Procedural Complications Not to Blame for Death After PCI

Live Case Procedures Just as Safe as in Daily Practice

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

PARTNER: TAVI Cost Effective Compared With Standard Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content